MBMichael R. Bailey

Michael R. Bailey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael R. Bailey has a total of 302 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fragmentation and Facilitated Clearance of Small, Asymptomatic, Renal Stones with Burst Wave Lithotripsy and Ultrasonic Propulsion: A 14-Month Follow-Up

    by Jonathan D. Harper, Barbrina Dunmire, Jeff Thiel, Barbara H. Burke, Alana C. Desai, Manjiri Dighe, Branda J. Levchak, James E. Lingeman, Claire C. Yang, Michael R. Bailey, et al.

    Purpose: To evaluate if treating small asymptomatic renal stones with office-based burst wave lithotripsy (BWL) and ultrasonic propulsion (UP) prevents future stone growth, emergency department visits, and surgical procedures for stone care. Methods: Participants with 2–7 mm asymptomatic renal stones were treated with BWL to break stones and UP to facilitate clearance of fragments. The primary outcome measure was relapse, defined as stone growth, an urgent or emergent medical visit, or operation for the randomized stones of interest within 14 months of the procedure. These events would include visits caused by the treatment and the presence of residual stones. Relapse data from untreated control groups with small stones or fragments from three published contemporaneous studies with similar protocols and 1- to 5-year follow-up were pooled and inverse probability weighted for comparison. The cumulative incidence of relapse was estimated using the Kaplan–Meier method. Results: Between April 2023 and September 2024, 18 participants underwent treatment of 27 asymptomatic small stones; 7 (39%) participants underwent a second BWL procedure to complete treatment. The control group had significantly shorter time to relapse than the treatment group ( p = 0.048 by weighted log-rank test). The hazard ratio for relapse in the treatment group, compared with the control group, was less than 0.01 ( p < 0.001). There was no relapse in the treated group within 14 months. For comparison, the 1-year relapse rate was 26% in the control group. Conclusions: In a small feasibility study, no stone-related relapse events occurred within 14 months following treatment of small, asymptomatic renal stones with BWL and UP.

  • Open Access

    Burst wave lithotripsy for the treatment of obstructive ureteroliths in cats

    by Adam Hunt, Adam D Maxwell, Jody P Lulich, Michael R Bailey, Kaizer Contreras, Ga Won Kim, Richard Hermes, Marissa Y Torre, Michael S Borofsky, Eva Furrow

    Ureteroliths are a major source of morbidity and mortality in cats, and limited non-surgical options are available for their treatment. Ultrasound-guided, burst wave lithotripsy (BWL) is approved by the Food and Drug Administration to fragment renal and ureteral calculi noninvasively in awake human patients. Assess the safety and efficacy of a veterinary BWL device for the treatment of obstructive ureteroliths in cats. Eleven client-owned cats; 10 with unilateral ureteral obstruction and 1 with bilateral ureteral obstruction. In this single-arm clinical trial, BWL was performed under general anesthesia in treatments ≤90 min. Outcomes included apparent fragmentation, ureterolith passage, decrease in pyelectasia or hydroureter, and decrease in serum creatinine concentration. Adverse events were characterized by severity and relationship to BWL. In total, 12 ureters with 17 ureteroliths were treated with BWL. Five ureters received 1 treatment, 6 received 2, and 1 received 3, resulting in 20 total treatments. Ureterolith fragmentation was apparent in 11 of 12 treated ureters. Of 10 ureters with follow-up imaging, 8 had ureterolith passage and an accompanying decrease in ureteral dilatation. For the cats with ureterolith passage, the median serum creatinine concentration change was −29% (range, −56% to 28%) at 1-3 weeks. One serious BWL-related adverse event of worsening obstruction from residual fragments occurred, but was solved with retreatment. Burst wave lithotripsy shows promise as a minimally invasive treatment for obstructive ureteroliths in cats. With the system used in our study, more than 1 treatment was often necessary.

  • Facilitated Clearance of Small, Asymptomatic Renal Stones With Burst Wave Lithotripsy and Ultrasonic Propulsion

    by Jonathan D. Harper, Barbrina Dunmire, Jeff Thiel, Barbara H. Burke, Yak-Nam Wang, Stephanie Totten, John C. Kucewicz, Adam D. Maxwell, M. Kennedy Hall, Arturo E. Holmes, et al.

    We tested feasibility of burst wave lithotripsy (BWL) and ultrasonic propulsion to noninvasively fragment and expel small, asymptomatic, renal stones in awake participants. Adult patients suspected of having 2-7 mm stones were consented and screened for eligibility. BWL and ultrasonic propulsion were applied to up to three stones in one kidney of qualifying participants for a 30-minute total exposure. Participants completed a computed tomography (CT) scan and the Wisconsin stone quality-of-life questionnaire (WISQOL) within 90 days before and 120 days after the procedure. Participants were contacted weekly for 3 weeks following the procedure to assess adverse events (AEs). Outcomes included 1) no fragment > 2 mm, 2) unanticipated healthcare visits, 3) change in stone volume, 4) reported AEs, and 5) WISQOL score. Forty-one participants were enrolled between April 2023 and October 2024. Twenty-one participants failed screening because no stones were seen, stones were too large or small, stone visibility was too deep or obstructed, or they declined to participate. Twenty participants with 31 stones received the research procedure with seven undergoing a single repeat procedure. Twenty-two of 31 stones (71%) met the primary effectiveness outcome of no fragment > 2 mm with 17 of 31 stones (55%) reported as stone free. Median stone volume reduction (interquartile range) was 100% (88%-100%). No participants returned unexpectedly for care related to the procedure. AEs were all Grade I by modified Clavien classification. WISQOL scores improved on 10 of 15 completed questionnaires. Small, asymptomatic renal stones were effectively and safely removed in awake participants in a clinic setting.


  • Open Access

    Randomized Controlled Trial of Ultrasonic Propulsion–Facilitated Clearance of Residual Kidney Stone Fragments vs Observation

    by Mathew D. Sorensen, Barbrina Dunmire, Jeff Thiel, Bryan W. Cunitz, Barbara H. Burke, Branda J. Levchak, Christina Popchoi, Arturo E. Holmes, John C. Kucewicz, M. Kennedy Hall, et al.

    Ultrasonic propulsion is an investigational procedure for awake patients. Our purpose was to evaluate whether ultrasonic propulsion to facilitate residual kidney stone fragment clearance reduced relapse. This multicenter, prospective, open-label, randomized, controlled trial used single block randomization (1:1) without masking. Adults with residual fragments (individually ≤5 mm) were enrolled. Primary outcome was relapse as measured by stone growth, a stone-related urgent medical visit, or surgery by 5 years or study end. Secondary outcomes were fragment passage within 3 weeks and adverse events within 90 days. Cumulative incidence of relapse was estimated using the Kaplan-Meier method. Log-rank test was used to compare the treatment (ultrasonic propulsion) and control (observation) groups. The trial was conducted from May 9, 2015, through April 6, 2024. Median follow-up (interquartile range) was 3.0 (1.8-3.2) years. The treatment group (n = 40) had longer time to relapse than the control group (n = 42; P < .003). The restricted mean time-to-relapse was 52% longer in the treatment group than in the control group (1530 ± 92 days vs 1009 ± 118 days), and the risk of relapse was lower (hazard ratio 0.30, 95% CI 0.13-0.68) with 8 of 40 and 21 of 42 participants, respectively, experiencing relapse. Omitting 3 participants not asked about passage, 24 treatment (63%) and 2 control (5%) participants passed fragments within 3 weeks of treatment. adverse events were mild, transient, and self-resolving, and were reported in 25 treated participants (63%) and 17 controls (40%). Ultrasonic propulsion reduced relapse and added minimal risk. NCT02028559.


  • Open Access

    Application of novel burst wave lithotripsy and ultrasonic propulsion technology for the treatment of ureteral calculi in a bottlenose dolphin (Tursiops truncatus) and renal calculi in a harbor seal (Phoca vitulina)

    by Arturo E. Holmes, Ben H. Chew, Robert Laughlin, Jean Buckley, Erica Kiewice, Michael J. Dancel, David Blasko, Victor K. F. Wong, Abdulghafour Halawani, Kyo Chul Koo, et al.

    Marine mammals may develop kidney stones, which can be challenging to treat. We describe burst wave lithotripsy (BWL) and ultrasonic propulsion to treat ureteral calculi in a 48-year-old female bottlenose dolphin (Tursiops truncatus) and to reduce renal stone burden in a 23-year-old male harbor seal (Phoca vitulina). BWL and ultrasonic propulsion were delivered transcutaneously in sinusoidal ultrasound bursts to fragment and reposition stones. Targeting and monitoring were performed with real-time imaging integrated within the BWL system. Four dolphin stones were obtained and fragmented ex vivo. The dolphin case received a 10-min and a 20-min BWL treatment conducted approximately 24 h apart to treat two 8–10 mm partially obstructing right mid-ureteral stones, using oral sedation alone. For the harbor seal, while under general anesthesia, retrograde ureteroscopy attempts were unsuccessful because of ureteral tortuosity, and a 30-min BWL treatment was targeted on one 10-mm right kidney stone cluster. All 4 stones fragmented completely to < 2-mm fragments in < 20 min ex vivo. In the dolphin case, the ureteral stones appeared to fragment, spread apart, and move with ultrasonic propulsion. On post-treatment day 1, the ureteral calculi fragments shifted caudally reaching the ureteral orifice on day 9. On day 10, the calculi fragments passed, and the hydroureter resolved. In the harbor seal, the stone cluster was observed to fragment and was not visible on the post-operative computed tomography scan. The seal had gross hematuria and a day of behavior indicating stone passage but overall, an uneventful recovery. BWL and ultrasonic propulsion successfully relieved ureteral stone obstruction in a geriatric dolphin and reduced renal stone burden in a geriatric harbor seal.


  • Open Access

    Development of a burst wave lithotripsy system for noninvasive fragmentation of ureteroliths in pet cats

    by Adam D. Maxwell, Ga Won Kim, Eva Furrow, Jody P. Lulich, Marissa Torre, Brian MacConaghy, Elizabeth Lynch, Daniel F. Leotta, Yak-Nam Wang, Michael S. Borofsky, et al.

    Background: Upper urinary tract stones are increasingly prevalent in pet cats and are difficult to manage. Surgical procedures to address obstructing ureteroliths have short- and long-term complications, and medical therapies (e.g., fluid diuresis and smooth muscle relaxants) are infrequently effective. Burst wave lithotripsy is a non-invasive, ultrasound-guided, handheld focused ultrasound technology to disintegrate urinary stones, which is now undergoing human clinical trials in awake unanesthetized subjects. Results: In this study, we designed and performed in vitro testing of a modified burst wave lithotripsy system to noninvasively fragment stones in cats. The design accounted for differences in anatomic scale, acoustic window, skin-to-stone depth, and stone size. Prototypes were fabricated and tested in a benchtop model using 35 natural calcium oxalate monohydrate stones from cats. In an initial experiment, burst wave lithotripsy was performed using peak ultrasound pressures of 7.3 (n = 10), 8.0 (n = 5), or 8.9 MPa (n = 10) for up to 30 min. Fourteen of 25 stones fragmented to < 1 mm within the 30 min. In a second experiment, burst wave lithotripsy was performed using a second transducer and peak ultrasound pressure of 8.0 MPa (n = 10) for up to 50 min. In the second experiment, 9 of 10 stones fragmented to < 1 mm within the 50 min. Across both experiments, an average of 73–97% of stone mass could be reduced to fragments < 1 mm. A third experiment found negligible injury with in vivo exposure of kidneys and ureters in a porcine animal model. Conclusions: These data support further evaluation of burst wave lithotripsy as a noninvasive intervention for obstructing ureteroliths in cats.


  • Removal of Small, Asymptomatic Kidney Stones and Relapse

    by Mathew D. Sorensen, Michael R. Bailey, James E. Lingeman

    To the Editor: Sorensen et al. (Aug. 11 issue)1 found that the incidence of relapse of kidney stones at 5 years was lower among patients undergoing endoscopic removal of small, asymptomatic kidney stones (in the same procedure as the removal of primary symptomatic kidney stones) than among those who did not have removal of such secondary stones. However, the authors do not address two important issues. First, they do not describe long-term complications in the two trial groups, probably because only a few patients finished 5 years of follow-up.2 Second, we suggest that Figure 3 of their article is probably . . .


  • Open Access

    First Series Using Ultrasonic Propulsion and Burst Wave Lithotripsy to Treat Ureteral Stones

    by M. Kennedy Hall, Jeff Thiel, Barbrina Dunmire, Patrick C. Samson, Ross Kessler, Peter Sunaryo, Robert M. Sweet, Ian S. Metzler, Helena C. Chang, Martin Gunn, et al.

    Purpose:Our goal was to test transcutaneous focused ultrasound in the form of ultrasonic propulsion and burst wave lithotripsy to reposition ureteral stones and facilitate passage in awake subjects...